Phase I Trial of Escalating Doses of Anti-PD1 Monoclonal Antibody (CT-011) in Combination With p53 Vaccine in Adults With Advanced Solid Tumors.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Cancer vaccine-p53 (Primary) ; Pidilizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 30 Dec 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 30 Dec 2011 Planned end date changed from 1 Apr 2012 to 1 Oct 2011 as reported by ClinicalTrials.gov.